Skip to main content

Advertisement

SpringerLink
Log in

Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The prognosis of patients with hypoplastic myelodysplastic syndrome (hMDS) after receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. This study aimed to evaluate the outcomes of patients with hMDS after allo-HSCT. Between September 2013 and October 2019, a total of 20 consecutive patients with hMDS and 1 patient with clonal cytopenia of undermined significance (CCUS) who underwent allo-HSCT, which included procedures with 9 matched sibling donors, 2 matched unrelated donors, 4 mismatched unrelated donors and 6 haploidentical donors, were enrolled in this study. The median time for myeloid engraftment was 11 days (range 9–17 days), and that for platelet engraftment was 10 days (range 7–17 days). The cumulative incidence (CI) of myeloid and platelet recovery was 95.2 ± 6.0% and 90.5 ± 7.3%, respectively. The CI rates were 40.0 ± 11.3% for grades II–III acute graft-versus-host disease (GVHD), 36.8 ± 11.5% for chronic GVHD and 23.8 ± 9.6% for nonrelapse mortality. No patients experienced relapse. Sixteen surviving patients were followed up for a median of 1113 days (range 110–2305 days), and the overall survival and relapse-free survival rates were both 72.7 ± 10.6%. This limited retrospective analysis suggests that patients with hMDS had a favorable survival after allo-HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome. Cancer. 1988;62(5):958–64.

    CAS  PubMed  Google Scholar 

  2. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, Werner M, Choritz H, Mainzer K, et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol. 1993;66(3):117–22.

    CAS  PubMed  Google Scholar 

  3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–99.

    CAS  PubMed  Google Scholar 

  4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    CAS  PubMed  Google Scholar 

  5. Huang TC, Ko BS, Tang JL, Hsu C, Chen CY, Tsay W, et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia. 2008;22(3):544–50.

    PubMed  Google Scholar 

  6. Bono E, McLornan D, Travaglino E, Gandhi S, Galli A, Khan AA, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019;33(10):2495–505.

    CAS  PubMed  Google Scholar 

  7. Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, et al. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica. 2015;100(11):e434.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Calado RT. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol. 2011;38(5):667–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79(8):1548–51.

    CAS  PubMed  Google Scholar 

  10. Selleri C, Maciejewski JP, Catalano L, Ricci P, Andretta C, Luciano L, et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia. Cancer. 2002;95(9):1911–22.

    CAS  PubMed  Google Scholar 

  11. Marisavljevic D, Cemerikic V, Rolovic Z, Boskovic D, Colovic M. Hypocellular myelodysplastic syndromes: clinical and biological significance. Med Oncol. 2005;22(2):169–75.

    PubMed  Google Scholar 

  12. Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, et al. A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol. 2017;92(12):1324–32.

    CAS  PubMed  Google Scholar 

  13. JonÁšovÁ A, NeuwirtovÁ R, ČermÁk J, VozobulovÁ V, MocikovÁ K, ŠiškovÁ M, et al. Cyclosporin a therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100(2):304–9.

    PubMed  Google Scholar 

  14. Lim ZY, Killick S, Germing U, Cavenagh J, Culligan D, Bacigalupo A, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21(7):1436–41.

    CAS  PubMed  Google Scholar 

  15. Yoshimi A, Baumann I, Führer M, Bergsträsser E, Göbel U, Sykora K-W, et al. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica. 2007;92(3):397–400.

    CAS  PubMed  Google Scholar 

  16. Passweg JR, Giagounidis AAN, Simcock M, Aul C, Dobbelstein C, Stadler M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase iii trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99. J Clin Oncol. 2010;29(3):303–9.

    PubMed  Google Scholar 

  17. Fenaux P, Adès L. How we treat lower-risk myelodysplastic syndromes. Blood. 2013;121(21):4280–6.

    CAS  PubMed  Google Scholar 

  18. Killick SB, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164(4):503–25.

    CAS  PubMed  Google Scholar 

  19. Strahm B, Locatelli F, Bader P, Ehlert K, Kremens B, Zintl F, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant. 2007;40(4):329–33.

    CAS  PubMed  Google Scholar 

  20. Rzepecki P, Sarosiek T, Szczylik C. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome–single center experience. Jpn J Clin Oncol. 2006;36(1):46–9.

    PubMed  Google Scholar 

  21. Kim H, Lee J-H, Joo Y-D, Bae SH, Hyun MS, Lee J-H, et al. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Ann Hematol. 2012;91(9):1459–69.

    CAS  PubMed  Google Scholar 

  22. Hasegawa D, Chen X, Hirabayashi S, Ishida Y, Watanabe S, Zaike Y, et al. Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification. Br J Haematol. 2014;166(5):758–66.

    CAS  PubMed  Google Scholar 

  23. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol. 1995;91(3):612–7.

    CAS  PubMed  Google Scholar 

  24. Koh Y, Lee HR, Song EY, Kim HK, Kim I, Park S, et al. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA). Leuk Res. 2010;34(10):1344–50.

    PubMed  Google Scholar 

  25. Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126(21):2355–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.

    PubMed  Google Scholar 

  27. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70.

    CAS  PubMed  Google Scholar 

  28. Yoshimi A, Strahm B, Baumann I, Furlan I, Schwarz S, Teigler-Schlegel A, et al. Hematopoietic Stem Cell Transplantation in Children and Young Adults with Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Aplastic Anemia. Biol Blood Marrow Transplant. 2014;20(3):425–9.

    PubMed  Google Scholar 

  29. Wu L, Mo W, Zhang Y, Zhou M, Li Y, Zhou R, et al. Vascular and perivascular niches, but not the osteoblastic niche, are numerically restored following allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia. Int J Hematol. 2017;106(1):71–81.

    PubMed  Google Scholar 

  30. Xu S, Wu L, Zhang Y, Mo W, Zhou M, Li Y, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of severe aplastic anemia patients with infection: a single-center retrospective study. Biol Blood Marrow Transplant. 2018;24(12):2532–9.

    PubMed  Google Scholar 

  31. Zhang Y, Wu L, Mo W, Zhou M, Li Y, Chen X, et al. Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: a retrospective single-center study. Biol Blood Marrow Transplant. 2019;25(8):1567–75.

    PubMed  Google Scholar 

  32. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–17.

    CAS  PubMed  Google Scholar 

  33. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–8.

    CAS  PubMed  Google Scholar 

  34. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88.

    CAS  PubMed  Google Scholar 

  35. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820–9.

    PubMed  PubMed Central  Google Scholar 

  37. Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. haploidentical hematopoietic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2017;23(12):2143–50.

    PubMed  Google Scholar 

  38. Wang Y, Wang HX, Lai YR, Sun ZM, Wu DP, Jiang M, et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016;30(10):2055–63.

    CAS  PubMed  Google Scholar 

  39. Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189(6):1016–27. https://doi.org/10.1111/bjh.16206.

    Article  CAS  PubMed  Google Scholar 

  40. Kim S-Y, Le Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, et al. Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica. 2014;99(12):1868.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Mangaonkar AA, Ferrer A, Pinto EVF, Cousin MA, Kuisle RJ, Gangat N, et al. Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clin Proc. 2019;94(9):1753–68.

    PubMed  PubMed Central  Google Scholar 

  42. Robin M, Porcher R, Adès L, Boissel N, Raffoux E, Xhaard A, et al. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. Bone Marrow Transplant. 2013;48(10):1296–301.

    CAS  PubMed  Google Scholar 

  43. Saber W, Cutler CS, Nakamura R, Zhang M-J, Atallah E, Rizzo JD, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013;122(11):1974–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, et al. HLA-mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2019;25(1):114–20.

    PubMed  Google Scholar 

  45. Ayuk F, Beelen DW, Bornhauser M, Stelljes M, Zabelina T, Finke J, et al. Relative impact of hla matching and non-HLA donor characteristics on outcomes of allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24(12):2558–677.

    PubMed  Google Scholar 

  46. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105(1):410–9.

    CAS  PubMed  Google Scholar 

  47. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. The Lancet. 2000;355(9211):1231–7.

    CAS  Google Scholar 

  48. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.

    CAS  PubMed  Google Scholar 

  49. De Witte T, Brand R, Van Biezen A, Mufti G, Ruutu T, Finke J, et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol. 2009;146(6):627–36.

    PubMed  Google Scholar 

  50. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249–56.

    PubMed  PubMed Central  Google Scholar 

  51. Saber W, Horowitz MM. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematol Am Soc Hematol Educ Program. 2016;2016(1):478–84.

    Google Scholar 

  52. Tong W-G, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, et al. Predicting survival of patients with hypocellular myelodysplastic syndrome. Cancer. 2012;118(18):4462–70.

    PubMed  PubMed Central  Google Scholar 

  53. Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res. 2008;32(4):553–8.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by research funding from the Science Foundation of Guangzhou First People’s Hospital (M2019015), the Guangzhou General Science and Technology Project of Health and Family Planning (20181A011002), the Nature Science Foundation of Guangdong Province (2018A0303130179), the Special Fund for Clinical Research of the Chinese Media Association (16010050621), and the National Natural Science Foundation of China (81600147). We also acknowledge American Journal Experts for editing the manuscript.

Author information

Author notes

  1. Ming Zhou and Liangliang Wu contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People’s Republic of China

    Ming Zhou, Liangliang Wu, Yuping Zhang, Wenjian Mo, Yumiao Li, Xiaowei Chen, Caixia Wang, Shiyi Pan, Shilin Xu, Wei Zhou, Tingfen Deng & Shunqing Wang

Authors
  1. Ming Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liangliang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenjian Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yumiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaowei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Caixia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shiyi Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shilin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tingfen Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shunqing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shunqing Wang.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, M., Wu, L., Zhang, Y. et al. Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome. Int J Hematol 112, 825–834 (2020). https://doi.org/10.1007/s12185-020-02969-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02969-9

Keywords

Search

Navigation